Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

compounds.
  • On April 21, InterMune reported that the INFORM-1 study had been expanded by three additional cohorts to explore the interferon-free regimen in treatment-experienced patients, both treatment failures and null-responder HCV patients, and would include twice-daily dosing of ITMN-191 and significantly higher total daily doses (600mg and 900mg twice daily) than those explored in the first four patient cohorts.
  • Today the company announced that results of all seven cohorts of INFORM-1 will be presented in Presidential Plenary Session III (#193) at the 2009 AASLD meeting at 8:00 a.m. on November 3. The company also announced today that two additional abstracts on the topics of the PK/PD profile (#1594) and the viral resistance profile (#1585) of the INFORM-1 regimen have been accepted for poster presentations at the 2009 AASLD meeting, also on November 3.
  • 2009 Key Project Guidance

    The company provided the following guidance on its key development projects, pirfenidone and ITMN-191.

        Milestones And Key Events                              Expected Date
        -------------------------                              -------------
        Pirfenidone
        -----------
        Oral presentation on pirfenidone at ERS              September 14, 2009
        ---------------------------------------              ------------------
        Submission of pirfenidone NDA to FDA                            Q4 2009
        ------------------------------------                            -------
        Submission of pirfenidone MAA to EMEA                           Q1 2010
        -------------------------------------                           -------
    
        ITMN-191 (R7227)
        ---------------
        Phase 2b initiation by Roche ($20 million payment
         to InterMune)                                              August 2009
        -------------------------------------------------       
    '/>"/>
    SOURCE InterMune, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. InterMune to Release Second Quarter Financial Results on August 6
    2. InterMune to Present at Goldman Sachs Healthcare Conference
    3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
    4. InterMune to Release First Quarter Financial Results on April 30
    5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
    6. InterMune to Present at Canaccord Adams Hepatitis C Conference
    7. InterMune to Present at Citis 4th Annual Biotech Day
    8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
    9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
    10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
    11. InterMune Announces Issuance of U.S. Patent for ITMN-191
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... This webinar will focus on EMA and FDA ... biosimilars. , Regulatory frameworks are evolving many countries to ... complex nature of biopharmaceuticals makes the demonstration of biosimilarity ... Based on the specific aspects of biosimilar drug development ...
    (Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
    (Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
    (Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
    Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
    ... have turned simple baker,s yeast into a virtual army of ... Parkinson,s disease. In a study published online today in ... can rescue yeast cells from toxic levels of a protein ... very small proteins called cyclic peptides. Two of the cyclic ...
    ... ... to Global Agriculture , ... Moines, Iowa and Seattle, Wash. (Vocus) July 13, 2009 -- DuPont and ... agricultural productivity. , , , , ,Under the agreement, DuPont business Pioneer Hi-Bred ...
    ... NEWARK, N.J., July 13 BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin ... that at ATS Labs using the EPA required AOAC Sporicidal Test, ... 100% Total Kill of live spores in seven (7) minutes ... impregnated then knotted suture loops and porous cylinders is an extremely ...
    Cached Biology Technology:Novel drug discovery tool could identify promising new therapies for Parkinson's disease 2Novel drug discovery tool could identify promising new therapies for Parkinson's disease 3Novel drug discovery tool could identify promising new therapies for Parkinson's disease 4DuPont and Arzeda Collaborate to Develop Improved Crops to Increase Productivity 2DuPont and Arzeda Collaborate to Develop Improved Crops to Increase Productivity 3BioNeutral's Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms 2BioNeutral's Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms 3BioNeutral's Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms 4
    (Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
    (Date:4/17/2014)... A Kansas State University engineer has developed ... remotely detects improvised explosive devices. The same technique ... Dunn, the Steven M. and Kay L. Theede ... and nuclear engineering, and his research team have ... underground or in car trunks. The distance detection ...
    (Date:4/17/2014)... Europe, Asia and the United States are spreading across ... native honeybee populations at this time, according to an ... Nosema microsporidia and Varroa mites., ... these invasive pests, which suggests to us that the ... the United States currently are not necessary in East ...
    Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
    ... received infusions of their own T cells after the ... tumors responded to the therapy, which was pioneered by ... University of Pennsylvania. Penn Medicine researchers will present the ... Society of Hematology,s Annual Meeting and Exposition. The ...
    ... of the new "Black Marble" images of Earth at night ... Atmospheric Administration have noticed bright areas in the western part ... so lit up, many have asked? Away from the ... Suomi NPP satellite in these images comes from wildfires. In ...
    ... in German . Much celebration at ... (DFG) has approved funding for a long-term research project by ... University and Dr. Frank Spinath from Saarland University. They are ... of 4,000 pairs of twins living in Germany. The name ...
    Cached Biology News:Leukemia patients remain in remission more than 2 years after engineered T cell therapy 2Leukemia patients remain in remission more than 2 years after engineered T cell therapy 3German Research Foundation to fund globally unique twin study on social inequality 2
    ...
    ...
    ... designed for two-dimensional electrophoresis (2D) and ... in this marker have been selected ... a 2D gel. The pI range ... Mol wt: 17,000-89,000 Physical Form: ...
    ... is based on PI's experience in high-resolution ... a decade. PI Hexapods were originally used ... adjustments over wide ranges in small step ... freedom with 3 m minimum incremental motion ...
    Biology Products: